NYVEPRIA
Clinical safety rating: caution
Comprehensive clinical and safety monograph for NYVEPRIA (NYVEPRIA).
Granulocyte colony-stimulating factor (G-CSF) analogue that binds to G-CSF receptors, stimulating proliferation, differentiation, and release of neutrophils from bone marrow.
| Metabolism | Primarily eliminated by renal excretion; not extensively metabolized. |
| Excretion | Primarily cleared by non-linear (target-mediated) disposition; minimal renal excretion (<1% unchanged). Elimination is mainly via cellular internalization and catabolism. |
| Half-life | Terminal half-life is approximately 15–20 days; due to target-mediated clearance, half-life may be shorter in patients with higher tumor burden or earlier in treatment. |
| Protein binding | Approximately 30% bound to human plasma proteins (primarily albumin). |
| Volume of Distribution | Vd approximately 0.05–0.1 L/kg, consistent with limited extravascular distribution. |
| Bioavailability | Subcutaneous: approximately 80% (relative to intravenous). |
| Onset of Action | Subcutaneous: time to peak concentration is about 3–7 days; clinical effect (neutrophil count elevation) observed within 1–2 days after first dose. |
| Duration of Action | Sustained elevation of neutrophils for approximately 2–3 weeks following single subcutaneous injection; duration is dose-dependent. |
5 mcg/kg intravenously or subcutaneously once daily. Administer at least 24 hours after cytotoxic chemotherapy and at least 24 hours before the next chemotherapy cycle.
| Dosage form | INJECTABLE |
| Renal impairment | No dose adjustment required for any degree of renal impairment, including end-stage renal disease. |
| Liver impairment | No dose adjustment required for any degree of hepatic impairment (Child-Pugh class A, B, or C). |
| Pediatric use | Weight-based dosing: 5 mcg/kg intravenously or subcutaneously once daily. Safety and efficacy established in pediatric patients aged 1 month and older. |
| Geriatric use | No specific dose adjustment recommended. Clinical studies included patients 65 years and older; no overall differences in safety or efficacy observed compared to younger adults. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for NYVEPRIA (NYVEPRIA).
| Breastfeeding | No human data on excretion in breast milk. M/P ratio unknown. High molecular weight suggests minimal transfer, but caution due to potential for neonatal immunosuppression. Consider alternative or discontinue nursing. |
| Teratogenic Risk | Pregnancy Category C. First trimester: Animal studies show fetal harm (reduced fetal weight, skeletal variations) at doses below human exposure. Second/third trimester: No adequate human data; potential fetal harm due to maternal neutropenia/fever risk. Avoid unless benefit outweighs risk. |
■ FDA Black Box Warning
Splenic rupture, serious allergic reactions, and acute respiratory distress syndrome (ARDS) have occurred. Sickle cell disease patients may experience severe crisis. G-CSF products can stimulate malignant cell growth. Cytogenetic abnormalities and myelodysplastic syndrome (MDS) have been reported in patients with breast or lung cancer receiving chemotherapy and G-CSF.
| Serious Effects |
["History of serious allergic reactions to filgrastim products or pegfilgrastim","Concurrent use with chemotherapy and radiation therapy except as part of clinical trials (safety not established)","Known hypersensitivity to E. coli-derived proteins"]
| Precautions | ["Splenic rupture: Monitor for left upper quadrant pain or shoulder tip pain","Acute respiratory distress syndrome (ARDS): Evaluate patients who develop fever, lung infiltrates, or respiratory distress","Serious allergic reactions: Discontinue permanently if severe allergic reactions occur","Sickle cell disease crisis: Use with caution in sickle cell disease patients; consider alternative therapy if severe crisis occurs","Potential for malignant cell growth: Avoid use in patients with myeloid malignancies","Myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML): Monitor for cytopenias and hematologic abnormalities","Capillary leak syndrome: Monitor for signs of fluid retention","Glomerulonephritis: Monitor for hematuria, proteinuria, and renal function"] |
Loading safety data…
| Fetal Monitoring |
| Monitor maternal absolute neutrophil count (ANC) weekly during therapy. Fetal: Consider serial growth ultrasounds if used in pregnancy (limited data). Monitor for maternal infections (fever, symptoms). |
| Fertility Effects | No human fertility studies. Reproductive toxicity in animal studies includes reduced fertility indices at high doses (pre- and post-implantation loss). Human risk unknown. |